Hostname: page-component-848d4c4894-2xdlg Total loading time: 0 Render date: 2024-06-17T01:58:47.106Z Has data issue: false hasContentIssue false
  • English
  • Français

The sulphanilamide treatment of scarlet fever

Published online by Cambridge University Press:  15 May 2009

Jane O. French
Jane O. French
Affiliation:
Assistant Medical Officer, City of Coventry Public Health Department, Late Resident Assistant Physician, Ruchill Fever Hospital, Glasgow
Rights & Permissions [Opens in a new window]

Extract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

1. A series of 340 cases of scarlet fever was treated under controlled conditions, (a) with sulphanilamide or benzyl-sulphanilamide, and (b) without sulphanilamide.

2. There was an even distribution of the individual cases in respect of factors known to influence the course of the disease, such as (a) the duration of the disease before admission to hospital, and (b) the severity of the infection.

3. Treatment was carried out during the whole period of 4 weeks, which constitutes the average period of hospitalization in scarlet fever.

4. The dose employed was large: (a) patients 5 years of age and over receiving 1 g. 4 hourly (i.e. 5 g. a day) for the first 14 days in hospital, thereafter 1 g. t.i.d. (i.e. 3 g. a day) for 14 days; a maximum total dose of 112 g., and (b) patients under 5 years of age receiving 0.5 g. 4 hourly (i.e. 2.5 g. a day) for the first 14 days in hospital, thereafter 0.5 g., t.i.d. (i.e. 1.5 g. a day) for 14 days; a maximum total dosage of 56 g.

5. The results show that sulphanilamide had no significant effect upon the initial symptoms of scarlet fever, or upon the kind, incidence, or duration of later complications.

6. A large number of toxic reactions followed the use of both sulphanilamide and benzyl-sulphanilamide.

7. In view of all the evidence submitted, it is considered that there is no justification for the employment of sulphanilamide and benzyl-sulphanilamide in the treatment of scarlet fever.

Type
Research Article
Information
Journal of Hygiene , Volume 39 , Issue 5 , September 1939 , pp. 581 - 596
Copyright
Copyright © Cambridge University Press 1939

References

REFERENCES

Basman, J. & Perley, A. M. (1937). J. Pediat. 11, 212.CrossRefGoogle Scholar
Colebrook, L. & Kenny, M. (1936). Lancet, 1, 1279.CrossRefGoogle Scholar
Foulis, M. A. & Barr, J. B. (1937). Brit. med. J. 1, 445.CrossRefGoogle Scholar
French, J. O. (1939). Lancet, 2, p. 127.CrossRefGoogle Scholar
Goodall, E. W. & Washbourn, J. W. (1929). Infectious Diseases, 3rd ed. pp. 221 et seq. H. K. Lewis and Co. Ltd.Google Scholar
Hageman, P. O. & Blake, F. G. (1938). Amer. J. med. Sci. 195, 163.CrossRefGoogle Scholar
Hogarth, J. C. (1937). Brit. Med. J. 2, 1160.CrossRefGoogle Scholar
Ker, C. B. (1929). Infectious Diseases, 3rd ed. pp. 83et seq. Oxford Univ. Press.Google Scholar
Long, P. H. & Bliss, E. A. (1937). J. Amer. med. Ass. 108, 32.CrossRefGoogle Scholar
McIntosh, R., Wilcox, D. A. & Wright, F. H. (1937). J. Pediat. 11, 167.CrossRefGoogle Scholar
Mellon, R. R., Gross, P. & Cooper, F. B. (1937). J. Amer. med. Ass. 108, 1858.CrossRefGoogle Scholar
Mitchell, A. G. & Trachsler, W. H. (1937). J. Pediat. 11, 183.CrossRefGoogle Scholar
Muir, R. (1936). Text-book of Pathology, 4th ed. p. 675. Edward Arnold and Co.Google Scholar
Okell, C. C. (1932). Lancet, 1, 761, 815, 867.CrossRefGoogle Scholar
Osgood, E. E. & Brownlie, I. E. (1938). J. Amer. med. Ass. 110, 348.Google Scholar
Patterson, D. C. (1937). J. Conn. St. Med. Ass. 1, 358.Google Scholar
Peters, B. A. & Havard, R. V. (1937). Lancet, 1, 1273.CrossRefGoogle Scholar
Rolleston, J. D. (1929). Acute Infectious Diseases, 2nd ed. pp. 251. et seq. Wm. Heinemann, Ltd.Google ScholarPubMed
Sako, W., Dwan, P. F. & Platou, E. S. (1938). J. Amer. med. Ass. 110, 995.CrossRefGoogle Scholar